Ultrasound Guided Transfemoral Complex Large-bore PCI Trial

NCT ID: NCT04837404

Last Updated: 2023-06-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

544 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-06-09

Study Completion Date

2023-05-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

ULTRACOLOR is a randomized multicentre investigator-initiated study to investigate if ultrasound guided femoral access is associated with less clinically relevant access site related bleeding and/or vascular complications requiring intervention as compared to the fluoroscopy guided method for complex PCI with large-bore access.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

ULTRACOLOR is a prospective, multicentre, randomized investigator-initiated trial designed to enroll 542 subjects with an indication for PCI for complex coronary lesions.

This study will investigate if ultrasound guided femoral access is associated with less clinically relevant access site related bleeding and/or vascular complications requiring intervention as compared to the fluoroscopy guided method for complex PCI with large-bore access.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Complex Coronary Lesions Percutaneous Coronary Intervention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Prospective, multicentre, randomized investigator-initiated trial with a superiority design
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ultrasound guided femoral access

Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Ultrasound guided femoral access will be used.

Group Type OTHER

Ultrasound guided femoral access for complex PCI

Intervention Type PROCEDURE

Ultrasound guided femoral access for complex PCI

fluoroscopy guided femoral access

Patients who are planned for complex PCI requiring 7 or more French sheath and guiding catheters. Fluoroscopy guided femoral access will be used.

Group Type OTHER

Fluoroscopy guided femoral access for complex PCI

Intervention Type PROCEDURE

Fluoroscopy guided femoral access for complex PCI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ultrasound guided femoral access for complex PCI

Ultrasound guided femoral access for complex PCI

Intervention Type PROCEDURE

Fluoroscopy guided femoral access for complex PCI

Fluoroscopy guided femoral access for complex PCI

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Use of the femoral artery for primary or secondary access with ≥ 7 Fr guiding catheter as indication for complex PCI, according to the expertise of the treating physician.
2. Age 18 years or older.

Exclusion Criteria

1. Inability to obtain informed consent
2. Contra-indication for femoral access
3. Cardiogenic shock
4. ST elevation myocardial infarction
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Diagram B.V.

OTHER

Sponsor Role collaborator

Maatschap Cardiologie Zwolle

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maarten van Leeuwen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Isala

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CHU Charleroi

Charleroi, , Belgium

Site Status

Ziekenhuis Oost Limburg

Genk, , Belgium

Site Status

Jessa hospital

Hasselt, , Belgium

Site Status

Elisabeth-Krankenhaus

Essen, , Germany

Site Status

Amsterdam UMC

Amsterdam, , Netherlands

Site Status

Catharina hospital

Eindhoven, , Netherlands

Site Status

St Antonius

Nieuwegein, , Netherlands

Site Status

Radboudumc

Nijmegen, , Netherlands

Site Status

UMC Utrecht

Utrecht, , Netherlands

Site Status

Isala Hospital

Zwolle, , Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium Germany Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Meijers TA, Nap A, Aminian A, Schmitz T, Dens J, Teeuwen K, van Kuijk JP, van Wely M, Bataille Y, Kraaijeveld AO, Roolvink V, Dambrink JE, Gosselink ATM, Hermanides RS, Ottervanger JP, Tsilingiris I, van den Buijs DMF, van Royen N, van Leeuwen MAH. Ultrasound-guided versus fluoroscopy-guided large-bore femoral access in PCI of complex coronary lesions: the international, multicentre, randomised ULTRACOLOR Trial. EuroIntervention. 2024 Jul 15;20(14):e876-e886. doi: 10.4244/EIJ-D-24-00089.

Reference Type DERIVED
PMID: 38742577 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

9343

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.